Phase I/II Trial of Alectinib and Bevacizumab in Patients With Advanced, Anaplastic Lymphoma Kinase (ALK)-Positive, Non-Small Cell Lung Cancer

NCT02521051 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

11

Enrollment

OTHER

Sponsor class

Stopped slow accrual

Conditions

Non-Small Cell Lung Cancer (NSCLC)

Interventions

DRUG: Alectinib
DRUG: Bevacizumab

Sponsor

Massachusetts General Hospital

Collaborators

[object Object]